The risk of tuberculosis disease in rheumatoid arthritis patients on biologics and targeted therapy: A 15-year real world experience in Taiwan

PLoS ONE

Volumn 12, Issue 6, 2017, Pages

  Lim, Chong Hong ^a,b   Chen, Hsin Hua ^b,c,d   Chen, Yi Hsing ^b,c   Chen, Der Yuan ^b,c,d,e   Huang, Wen Nan ^b,c   Tsai, Jaw Ji ^b   Hsieh, Tsu Yi ^b   Hsieh, Chia Wei ^b   Hung, Wei Ting ^b   Lin, Ching Tsai ^b   Lai, Kuo Lung ^b   Tang, Kuo Tung ^b   Tseng, Chih Wei ^b   Chen, Yi Ming ^b,c,d  

^a Rheumatology Unit Department of Internal Medicine Pulau Pinang General Hospital   (Malaysia)

^b TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^e CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; ANTIRHEUMATIC AGENT; ETANERCEPT; GOLIMUMAB; SALAZOSULFAPYRIDINE; TOCILIZUMAB; TOFACITINIB; BIOLOGICAL PRODUCT;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DISEASE DURATION; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; INCIDENCE; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; TAIWAN; TUBERCULOSIS; ARTHRITIS, RHEUMATOID; COMPLICATION; MIDDLE AGED;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; FEMALE; HUMANS; MALE; MIDDLE AGED; TUBERCULOSIS;

EID: 85020005894     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0178035     Document Type: Article

References (32)

1. WHO. Global tuberculosis report 2016. 20th edition. http://www.who.int/tb/publications/global-report/en/.
2. Centers for Disease Control MoHaW, R.O.C.(Taiwan). Taiwan CDC Joins Hands With Industry, Government, And Academia To Reveal Accomplishments Of 10 Year Battle Against Tuberculosis (TB) With A Renewed Commitment To Eliminating The Disease. 2016. Web. 17 Nov. 2016.
3. Carmona L, Hernandez-Garcia C, Vadillo C, Pato E, Balsa A, Gonzalez-Alvaro I, et al. Increased risk of tuberculosis in patients with rheumatoid arthritis. The Journal of rheumatology. 2003; 30: 1436-1439. PMID: 12858438
4. Yasui K. Immunity against Mycobacterium tuberculosis and the risk of biologic anti-TNF-reagents. Pediatr Rheumatol Online J. 2014; 12(45).
5. Stenger S. Immunological control of tuberculosis: Role of tumour necrosis factor and more. Annals of the rheumatic diseases. 2005; 64 Suppl 4:iv24-8.
6. Barnes PF, Wizel B. Type 1 cytokines and the pathogenesis of tuberculosis. American journal of respiratory and critical care medicine. 2000; 161: 1773-1774. https://doi.org/10.1164/ajrccm.161.6.16167 PMID: 10852738
7. Cantini F, Goletti D. Biologics and tuberculosis risk: The rise and fall of an old disease and its new resurgence. The Journal of rheumatology Supplement. 2014; 91: 1-3. https://doi.org/10.3899/jrheum. 140095 PMID: 24788993
8. Arkema EV, Jonsson J, Baecklund E, Bruchfeld J, Feltelius N, Askling J. Are patients with rheumatoid arthritis still at an increased risk of tuberculosis and what is the role of biological treatmentsAnnals of the rheumatic diseases. 2015; 74: 1212-1217. https://doi.org/10.1136/annrheumdis-2013-204960 PMID: 24608401
9. Tubach F, Salmon D, Ravaud P, Allanore Y, Goupille P, Breban M, et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis and rheumatism. 2009; 60: 1884-1894. https://doi.org/10.1002/art.24632 PMID: 19565495
10. Rubbert-Roth A. Assessing the safety of biologic agents in patients with rheumatoid arthritis. Rheumatology. 2012; 51 Suppl 5:v38-47.
11. Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, Takeuchi T, et al. Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: Interim analysis of 3881 patients. Annals of the rheumatic diseases. 2011; 70: 2148-2151. https://doi.org/10.1136/ard.2011.151092 PMID: 21852254
12. Weinblatt ME, Moreland LW, Westhovens R, Cohen RB, Kelly SM, Khan N, et al. Safety of abatacept administered intravenously in treatment of rheumatoid arthritis: Integrated analyses of up to 8 years of treatment from the abatacept clinical trial program. The Journal of rheumatology. 2013; 40: 787-797. https://doi.org/10.3899/jrheum.120906 PMID: 23588946
13. Winthrop KL, Park SH, Gul A, Cardiel MH, Gomez-Reino JJ, Tanaka Y, et al. Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis. Annals of the rheumatic diseases. 2016; 75: 1133-1138. https://doi.org/10.1136/annrheumdis-2015-207319 PMID: 26318385
14. Liao TL, Lin CH, Shen GH, Chang CL, Lin CF, Chen DY. Risk for Mycobacterial Disease among Patients with Rheumatoid Arthritis, Taiwan, 2001-2011. Emerging infectious diseases. 2015; 21: 1387-1395. https://doi.org/10.3201/eid2108.141846 PMID: 26196158
15. Ke WM, Chen LS, Parng IM, Chen WW, On AW. Risk of tuberculosis in rheumatoid arthritis patients on tumour necrosis factor-alpha inhibitor treatment in Taiwan. The international journal of tuberculosis and lung disease: The official journal of the International Union against Tuberculosis and Lung Disease. 2013; 17: 1590-1595.
16. Chiu YM, Lang HC, Lin HY, Yang MT, Fang CH, Yang YW, et al. Risk of tuberculosis, serious infection and lymphoma with disease-modifying biologic drugs in rheumatoid arthritis patients in Taiwan. Int J Rheum Dis. 2014; 17 Suppl 3: 9-19.
17. Chen YH, Su WJ, Shen GH, Chen DY, Lu LY, Huang DF, et al. Screening and management of tuberculosis infection in patients scheduled for tumor necrosis factor-alpha inhibitors: Consensus recommendations from the Taiwan Rheumatology Association [Chinese]. Formosan Journal of Rheumatology. 2012; 26: 8-14.
18. Lo HY, Yang SL, Chou P, Chuang JH, Chiang CY. Completeness and timeliness of tuberculosis notification in Taiwan. BMC public health. 2011; 11:915. https://doi.org/10.1186/1471-2458-11-915 PMID: 22151346
19. Chen DY, Shen GH, Chen YM, Chen HH, Hsieh CW, Lan JL. Biphasic emergence of active tuberculosis in rheumatoid arthritis patients receiving TNFalpha inhibitors: The utility of IFNgamma assay. Annals of the rheumatic diseases. 2012; 71: 231-237. https://doi.org/10.1136/annrheumdis-2011-200489 PMID: 22021896
20. Cantini F, Nannini C, Niccoli L, Iannone F, Delogu G, Garlaschi G, et al. Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice. Autoimmunity reviews. 2015; 14: 503-509. https://doi.org/10.1016/j.autrev.2015.01. 011 PMID: 25617816
21. Lobue P, Menzies D. Treatment of latent tuberculosis infection: An update. Respirology. 2010; 15: 603-622. https://doi.org/10.1111/j.1440-1843.2010.01751.x PMID: 20409026
22. Brode SK, Jamieson FB, Ng R, Campitelli MA, Kwong JC, Paterson JM, et al. Increased risk of mycobacterial infections associated with anti-rheumatic medications. Thorax. 2015; 70: 677-682. https://doi.org/10.1136/thoraxjnl-2014-206470 PMID: 25911222
23. Brassard P, Kezouh A, Suissa S. Antirheumatic drugs and the risk of tuberculosis. Clinical infectious diseases: An official publication of the Infectious Diseases Society of America. 2006; 43: 717-722.
24. Lorenzetti R, Zullo A, Ridola L, Diamanti AP, Lagana B, Gatta L, et al. Higher risk of tuberculosis reactivation when anti-TNF is combined with immunosuppressive agents: A systematic review of randomized controlled trials. Annals of medicine. 2014; 46: 547-554. https://doi.org/10.3109/07853890.2014. 941919 PMID: 25105206
25. Rainsford KD, Parke AL, Clifford-Rashotte M, Kean WF. Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. Inflammopharmacology. 2015; 23: 231-269. https://doi.org/10.1007/s10787-015-0239-y PMID: 26246395
26. Flynn JL, Chan J. Immunology of tuberculosis. Annual review of immunology. 2001; 19: 93-129. https://doi.org/10.1146/annurev.immunol.19.1.93 PMID: 11244032
27. Lim C-H, Lin C-H, Chen D-Y, Chen Y-M, Chao W-C, Liao T-L, et al. One-Year Tuberculosis Risk in Rheumatoid Arthritis Patients Starting Their First Tumor Necrosis Factor Inhibitor Therapy from 2008 to 2012 in Taiwan: A Nationwide Population-Based Cohort Study. PloS one. 2016; 11:e0166339. https://doi.org/10.1371/journal.pone.0166339 PMID: 27832150
28. Brassard P, Lowe AM, Bernatsky S, Kezouh A, Suissa S. Rheumatoid arthritis, its treatments, the risk of tuberculosis in Quebec, Canada. Arthritis and rheumatism. 2009; 61: 300-304. https://doi.org/10.1002/art.24476 PMID: 19248128
29. Xie X, Li F, Chen JW, Wang J. Risk of tuberculosis infection in anti-TNF-alpha biological therapy: From bench to bedside. Journal of microbiology, immunology, infection = Wei mian yu gan ran za zhi. 2014; 47: 268-274. https://doi.org/10.1016/j.jmii.2013.03.005 PMID: 23727394
30. Kay J, Fleischmann R, Keystone E, Hsia EC, Hsu B, Mack M, et al. Golimumab 3-year safety update: An analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. Annals of the rheumatic diseases. 2015; 74: 538-546. https://doi.org/10.1136/annrheumdis-2013-204195 PMID: 24344160
31. Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, Takeuchi T, et al. Effectiveness and safety of tocilizumab: Postmarketing surveillance of 7901 patients with rheumatoid arthritis in Japan. The Journal of rheumatology. 2014; 41: 15-23. https://doi.org/10.3899/jrheum.130466 PMID: 24187110
32. Westhovens R, Kremer JM, Moreland LW, Emery P, Russell AS, Li T, et al. Safety and efficacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritis receiving background methotrexate: A 5-year extended phase IIB study. The Journal of rheumatology. 2009; 36: 736-742. https://doi.org/10.3899/jrheum.080813 PMID: 19273451